Mycophenolate mofetil

Base Information

• Chemical Name: Mycophenolate mofetil
• CAS No.: 115007-34-6
• Molecular Formula: C23H31NO7
• Molecular Weight: 433.502
• Hs Code.: 2934999090
• Mol file: 115007-34-6.mol

Synonyms:2-(4-Morpholinyl)ethyl 6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methyl-4-hexenoate;Mycophenolate mofetil;

Chemical Property of Mycophenolate mofetil

Chemical Property:

• Vapor Pressure: 7.51E-17mmHg at 25°C
• Melting Point: 93-94oC
• Refractive Index: 1.557
• Boiling Point: 637.6oC at 760 mmHg
• Flash Point: 339.4oC
• PSA: 94.53000
• Density: 1.222 g/cm3
• LogP: 2.46190
• Solubility.: Practically insoluble in water, freely soluble in acetone, sparingly soluble in anhydrous ethanol.

Purity/Quality:

99%MIN ^*data from raw suppliers

Mycophenolate Mofetil ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Uses: It is mainly used for prevention the allograft rejection reaction upon organ transplant as mostly seen in renal transplant and also suitable in the heat, liver transplant especially for the refractory rejection reaction after the transplant. It can be combined together with cyclosporine and corticosteroids. It can also be applied to rheumatoid arthritis, systemic lupus erythematosus, primary glomerulonephritis, psoriasis and some other autoimmune diseases. Apply oral administration in kidney transplant; initial dose: 2~3mg/kg per day, maintenance dose: 1~2mg/ kg per day and take in 2 to 3 times. The dose can be adjusted according to specific condition. Rheumatoid arthritis: 300 mg daily. Inhibitor of nucleic acid synthesis; immunomodulator. Mycophenolate Mofetil is an intermediate in the synthesis of (4Z)-Mycophenolate Mofetil (M831455), a degradation product of Mycophenolate mofetil, an immunosuppressant.
• Indications: Mycophenolate mofetil (CellCept), in conjunction with cyclosporine and corticosteroids, has clinical applications in the prevention of organ rejection in patients receiving allogeneic renal and cardiac transplants. By effectively inhibiting de novo purine synthesis, it can impair the proliferation of both T and B lymphocytes. Following oral administration, mycophenolate mofetil is almost completely absorbed from the GI tract, metabolized in the liver first to the active compound mycophenolic acid, and then further metabolized to an inactive glucuronide. Early clinical trials indicate that mycophenolate mofetil in conjunction with cyclosporine and corticosteroids is a more effective regimen than azathioprine in preventing the acute rejection of transplanted organs. GI side effects are most common.

Technology Process of Mycophenolate mofetil

There total 16 articles about Mycophenolate mofetil which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 89.5%

2-(morpholin-4-yl)ethanol (622-40-2) + methyl mycophenolate (31858-66-9) → mycophenolate mofetil (115007-34-6)

Guidance literature:

di(n-butyl)tin oxide; In toluene; at 120 ℃; for 24h;

Reference yield: 85.0%

→ mycophenolate mofetil (115007-34-6)

Guidance literature:

With pyrographite; In isopropyl alcohol; acetone; at -5 - 45 ℃; for 16 - 18h; Purification / work up;

Reference yield: 84.0%

2-(morpholin-4-yl)ethanol (622-40-2) + mycophenolic acid (24280-93-1) → mycophenolate mofetil (115007-34-6)

Guidance literature:

toluene-4-sulfonic acid; at 160 ℃; for 5h; Product distribution / selectivity;

upstream raw materials:

2-(morpholin-4-yl)ethanol

triethylamine mycophenolate

6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid dibenzylamine salt

6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid N,N,N',N'-tetramethylethylenediamine salt

Downstream raw materials:

2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate hydrochloride